Relationship Between the Plasma Concentration of C-Reactive Protein and Severity of Peripheral Arterial Disease by De Haro, Joaquin et al.
Clinical Medicine: Cardiology 2009:3 1–7 1
ORIGINAL RESEARCH
Correspondence: Dr. Joaquin De Haro Miralles, C/Playa de América 24, 28669, Boadilla del Monte, Madrid, 
Spain. Tel: +00 34 626022977; Email: deharojoaquin@yahoo.es
Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the 
Creative Commons Attribution By licence. For further information go to: http://creativecommons.org/licenses/by/3.0/.
Relationship Between the Plasma Concentration 
of C-Reactive Protein and Severity of Peripheral Arterial Disease
Joaquin De Haro, Francisco Acin, Francisco Jose Medina, Alfonso Lopez-Quintana, 
and Jose Ramon March
Department of Angiology and Vascular Surgery, Getafe University Hospital.
Abstract
Objective: To determine whether the increase in plasma levels of C-Reactive Protein (CRP), a non-speciﬁ  c reactant in the 
acute-phase of systemic inﬂ  ammation, is associated with clinical severity of peripheral arterial disease (PAD).
Methods and Results: This is a cross-sectional study at a referral hospital center of institutional practice in Madrid, Spain. 
A stratiﬁ  ed random sampling was done over a population of 3370 patients with symptomatic PAD from the outpatient vas-
cular laboratory database in 2007 in the order of their clinical severity: the ﬁ  rst group of patients with mild chronological 
clinical severity who did not require surgical revascularization, the second group consisted of patients with moderate clinical 
severity who had only undergone only one surgical revascularization procedure and the third group consisted of patients who 
were severely affected and had undergone two or more surgical revascularization procedures of the lower extremities in 
different areas or needed late re-interventions. The Neyman afﬁ  xation was used to calculate the sample size with a ﬁ  xed 
relative error of 0.1. A homogeneity analysis between groups and a unifactorial analysis of comparison of medians for CRP 
was done. The groups were homogeneous for age, smoking status, Arterial Hypertension HTA, diabetes mellitus, dyslipemia, 
homocysteinemia and speciﬁ  c markers of inﬂ  ammation. In the unifactorial analysis of multiple comparisons of medians 
according to Scheffé, it was observed that the median values of CRP plasma levels were increased in association with higher 
clinical severity of  PAD (3.81 mg/L [2.14–5.48] vs. 8.33 [4.38–9.19] vs. 12.83 [9.5–14.16]; p   0.05) as a unique factor of 
tested ones.
Conclusion: Plasma levels of CRP are associated with not only the presence of atherosclerosis but also with its chrono-
logical clinical severity.
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Introduction
Laboratory and experimental evidence have shown that inﬂ  ammatory processes play a central role 
in the development, progression and outcomes of atherosclerosis. Several studies suggest that patients 
at high risk of developing atherothrombotic disease suffer from chronic systemic inﬂ  ammation.
1 
More speciﬁ  cally, increased levels of C-Reactive Protein (CRP), a seric marker of systemic inﬂ  am-
mation, have been associated with a higher risk of: acute myocardial infarction or sudden death in 
patients diagnosed with either stable or unstable angina,
2 symptomatic ischemic coronary disease in 
elderly patients,
3 death caused by coronary disease
4 and ﬁ  rst episodes of myocardial infarction or 
cerebral ischemic stroke in otherwise apparently healthy people.
1 Likewise, some hypotheses propose 
that the seric concentration of CRP could have a predictive value in preclinical atherosclerosis as a 
molecular indicator of the severity of the disease. Indeed, recent research concludes that high-sensi-
tivity measurements of CRP provide an adjunctive method for global assessment of cardiovascular 
risk, in addition to traditional screening methods.
5 Thus, CRP plasma levels would add information 
of prognostic value to that obtained from plasma lipid levels based on Framingham study-based 
criteria.
6
Peripheral Arterial Disease (PAD) includes all the clinical entities resulting from arterial blood ﬂ  ow 
obstruction, excluding coronary and intracranial vascular beds. In this paper, the focus is on PAD 
affecting just the lower extremities.2
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Currently, there are few data relating CRP levels 
to PAD. Evidence
7 is found suggesting that 
increased basal levels of CRP in otherwise healthy 
people are associated with a higher risk of 
intermittent claudication and peripheral surgical 
revascularization.
Objective
The aim of this study is to determine whether the 
increase in CRP concentration, a non-specific 
reactant in the acute-phase of systemic inﬂ  amma-
tion that can be easily and reliably measured, is 
associated with clinical severity of PAD.
Material and Methods
A prospective cross-sectional study was designed 
in order to ﬁ  nd out a possible relationship between 
CRP plasma levels and the clinical severity of PAD 
in a target population of patients with PAD, in the 
south of Madrid in Spain with a population of 
3 million. For this purpose, a random sample of 
the target population was used and they were 
classiﬁ  ed as described below, which allowed a 
prospective assessment of the inflammation 
markers in a well-established gradation according 
to the aggression of the disease at the time of pre-
sentation.
The study population was made up of 3370 
patients diagnosed with PAD registered in the 
outpatient vascular laboratory database of this 
hospital. All patients were documented with, at 
least, a hemodynamic study with arterial Doppler 
of the lower extremities that demonstrated an 
ankle-brachial index lower than 0, 8.
With the purpose of evaluating the association 
between CRP plasma levels and the clinical form 
of PAD developed, three patient groups were 
formed as follows:
•  Group 1: patients with symptomatic PAD in 
the lower extremities who did not require surgi-
cal revascularization
•  Group 2: patients with symptomatic PAD in 
the lower extremities who had undergone only 
one surgical revascularization procedure (either 
open or endovascular surgery) of the lower 
extremities (in the aorto-iliac or infra-inguinal 
area) before December 31st 2005
{  (A latent period of 12 months without an 
operation is considered to be a sign of no 
progression of the disease).
•  Group 3: patients with symptomatic PAD in 
the lower extremities who had undergone two 
or more surgical revascularization procedures 
(either open or endovascular surgery) of the 
lower extremities ( in the aorto-iliac or infra-
inguinal area) in different areas or patients with 
symptomatic PAD in the lower extremities 
who needed another procedure in the same area 
with a delay of more than 12 months between 
procedures
•  (The aorto-iliac area is considered to be differ-
ent from the infra-inguinal area, and this last 
one also considered to be a different area from 
that of the lower limbs).
The total population of  3370 patients were divided 
according to their clinical presentation into the 
three above-mentioned groups resulting in 2900, 
380 and 90 patients respectively.
The Neyman’s afﬁ  xation was used to calculate 
the sample size needed for each stratus (N1, N2, N3).
8 
For a ﬁ  xed relative error of 0.1 calculated for the 
average, the sample size had to be 51 patients. 
The afﬁ  xations were then calculated according 
to Neyman to calculate the size of each stratus: 
N1 = 23; N2 = 17; N3 = 10. Therefore, 330 patients 
were randomly chosen from the different groups: 
150 from the ﬁ  rst group, 130 from the second and 
50 from the third. All the patients who had had any 
infectious disease or other acute illness such as 
acute coronary or limb ischemia, and those who 
had undergone any surgical procedure within a 
16-week period were excluded from the study, in 
order to control any possible bias by elevated CRP 
levels resulting due to these processes. Any patient 
with foot ulcers was also excluded.
Blood samples were taken from all of them, 
followed by standard blood processing and storing 
procedures. The plasma CRP levels along with the 
plasma lipidic proﬁ  le (total cholesterol levels, tri-
glycerides and HDL, LDL and VLDL lipoproteins), 
the plasma homocystein concentration, serum 
creatinine level and the glycosylated hemoglobin 
level of each patient were determined. A complete 
blood count was done. Clinical history about the 
cardiovascular risk factors, associated medication 
and symptoms of ischemia were obtained from the 
patients through individual interviews. At the time 
of blood sampling, all patients were in a Rutherford 
category of three or minor.
The CRP plasma concentrations were deter-
mined by an automatic ultrasensitive immunoassay 3
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(Roche Diagnostics GMBH) with a lower-limit 
detection of 0.2 mg/L and a coefﬁ  cient of variation 
of 4.2% in 4 mg/L and 6.3% in 1 mg/L.
The CRP plasma concentration median within 
each group was calculated along with the statistical 
signiﬁ  cance in the differences found between them 
by means of stratiﬁ  ed unifactorial analysis of mul-
tiple comparisons of medians according to Schaffé, 
who uses the F Distribution of Snedecor, which is 
not inﬂ  uenced by a lack of homogeneity within the 
groups.
8
The homogeneity within the groups was 
checked regarding CRP plasma levels and the fol-
lowing variables: age, smoking status, hyperten-
sion, diabetes, hyperlipidemia and lipidic plasma 
proﬁ  le, COPD, coronary heart disease, cerebro-
vascular disease, homocysteinemia, serum creati-
nine levels, LDH plasma levels, and leukocytes, 
neutrophils, lymphocytes and reticulocytes.
A multivariant analysis among groups was also 
performed to rule out possible confounding factors 
for the following variables: age, smoking status, 
hypertension, diabetes, hyperlipidemia and lipidic 
plasma proﬁ  le, COPD, coronary heart disease, 
cerebrovascular disease, homocysteinemia, serum 
creatinine levels, blood markers of acute inﬂ  am-
mation (leukocytosis, neutrophilia, basophilia, 
eosinophilia, monophilia, percentage of reticulo-
cytes) and associated anti-inﬂ  ammatory medica-
tion (aspirin and trifusal prescribed for PAD and 
steroid and non-steroid anti-inﬂ  ammatory drugs 
prescribed for other diseases).
All the variable data were expressed as 
median ± standard deviation except the variable 
CRP, expressed as median [quartil25–quartil75].
A p-value   0.05 was considered to be signiﬁ  cant.
Results
Table 1 displays the univariate analysis of clinical 
and analytical characteristics that are currently 
known as being associated with PAD. No signiﬁ  cant 
Table 1. Cardiovascular risk factors.
Patients with 
no surgical 
revascularization 
(Group 1)
Patients with 
only 1 
revascularization 
(Group 2)
Patients with 
2 or more 
revascularizations 
(Group 3)
p-value
Sample size 150 130 50
Age (mean) 66.87 ± 2.1 62.41 ± 3.1 66.91 ± 1.9 0.443
Smoking (%) 26.08 35.29 45.45 0.263
HTA (%) 65.21 70.58 81.81 0.341
Diabetes (%) 60.86 17.64 36.36 0.068
Dyslipemia (%) 52.17 58.82 27.27 0.273
COPD (%) 13.04 11.76 9.09 0.750
Coronary
disease (%) 30.43 47.05 36.36 0.595
Cerebrovascular 
disease (%)
8.69 11.76 9.09 0.917
Homocysteinemia
(μmol/L)
10.88 ± 1.1 10.10 ± 0.8 10.02 ± 0.9 0.853
Total cholesterolemia 
(mg/dL)
197.39 ± 11.6 204 ± 19 185.36 ± 2101 0.864
HDL (mg/dL) 56.17 ± 7.1 58 ± 5.9 46.64 ± 6.8 0.063
LDL (mg/dL) 120.30 ± 14 112.76 ± 13.9 106.73 ± 10.3 0.652
VLDL (mg/dL) 23.43 ± 5.7 31.82 ± 5 33.91 ± 6.3 0.390
Trigliceridemia (mg/dL) 123.61 ± 11.9 146.53 ± 13 158.91 ± 14.3 0.488
Creatininemia (mg/dL) 1.05 ± 0.1 0.93 ± 0.08 1.45 ± 0.1 0.523
HbA1c (%) 6.51 6.04 5.87 0.5714
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differences were found in any of the variables 
studied (age, cardiovascular risk factors such as 
smoking, hypertension, diabetes, dyslipemia, 
COPD, plasma homocystein levels, lipidic proﬁ  le 
or serum creatinine levels—a renal failure marker) 
that could act as confounding factors in the study 
of the association between CRP plasma levels and 
clinical severity of PAD.
No signiﬁ  cant difference was found in the com-
position of the groups relating to the existence of 
atherosclerotic disease in the coronary and cerebral 
vascular beds.
These results also show homogeneity between 
the groups relating to cardiovascular risk factors.
The multivariate analysis made on the factors 
associated with PAD stages resulted in no signiﬁ  -
cant differences for any variable.
Table 2 displays plasma levels of specific 
markers of inﬂ  ammation and blood counts in each 
clinical group at the time of plasma CRP level 
testing. There were no differences between groups 
for any tested marker and the levels show that 
there was no acute inﬂ  ammatory process at the 
time of blood sampling that could have affected 
the study.
No difference was found between groups 
concerning associated medication that could have 
affected CRP plasma levels: statins, ACE-inhibi-
tors, angiotensin receptor blockers and beta 
blockers.
Intragroup homogeneity test applied to CRP 
plasma levels and all the variables obtained from 
multivariate analysis among the groups show 
homogeneity in each group for all variables.
Once the intragroup homogeneity was tested 
the data of CRP plasma levels were analysed 
(Table 3).
In the unifactorial analysis of multiple com-
parisons of medians according to Scheffé for CRP 
plasma levels, it was found that in each group, an 
F statistic value of 24.113 was obtained which 
showed a significant grade much lower than 
0.05 (ca. 0.000), thereby demonstrating a statisti-
cally signiﬁ  cant difference between CRP plasma 
levels of the patients grouped according to the 
clinical severity of their PAD. This suggests, there-
fore, the existence of a consistent relationship 
between both variables.
As it can seen, median values of CRP plasma 
levels were increased in association with higher 
clinical severity of PAD (3.81 mg/L; 8.33 mg/L; 
12.83 mg/L) (Figure 1). These data indicate a direct 
relationship between CRP plasma levels and 
clinical severity of PAD.
Discussion
The data presented here allows the inference 
that there exists an association in patients with 
symptomatic PAD between their CRP plasma 
levels and the way the disease develops clinically. 
In previous studies the CRP basal levels in 
apparently healthy patients have already been 
linked to the risk of developing symptomatic PAD.
7 
Therefore, the results obtained here allow widening 
of the previously acknowledged role of CRP as a 
marker of vascular risk, not only in the coronary 
and cerebral beds but also in the peripheral circu-
Table 2. Speciﬁ  c markers of inﬂ  ammation.
Patients with 
no surgical 
revascularization 
(Group 1)
Patients with 
only 1 
revascularization 
(Group 2)
Patients with 
2 or more 
revascularizations 
(Group 3)
p-value
Leucocytes (10
3/μl) 7.663 ± 1.1 8.373 ± 1.3 7.247 ± 1.2 0.100
Neutrophils (10
3/μl) 4.646 ± 0.9 4.691 ± 0.8 4.281 ± 0.4 0.519
Lymphocytes (10
3/μl) 1.992 ± 0.25 2.642 ± 0.8 1.762 ± 0.9 0.796
Monocytes (10
3/μl) 0.582 ± 0.2 0.577 ± 0.1 0.396 ± 0.15 0.190
Eosinophils (10
3/μl) 0.296 ± 0.11 0.272 ± 0.11 0.478 ± 0.13 0.884
Basophils (10
3/μl) 4.043E-02 ± 0.26 4.529E-02 ± 1.2 3.818E-02 ± 1.9 0.234
Reticulocytes (%) 1.114 1.244 1.467 0.216
LDH (U/L) 325.83 ± 22 330.53 ± 32 365.18 ± 41 0.106
No statistical differences for major cardiovascular risk factors between groups.5
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lation, associating it directly with the severity and 
extension of PAD.
From a more integrative perspective based upon 
the results of this study and those of previous 
studies,
1–4,7 it may be hypothesized that CRP could 
serve as a molecular marker of the presence and 
clinical severity of systemic atherosclerotic disease.
Studies trying to prove the role of CRP in car-
diovascular risk assessment use “high-sensitive” 
CRP measurements since standard clinical assays 
for CRP typically have a lower detection limit of 
1 to 3 mg/L. Thus, these assays lack sensitivity 
within the low-normal range and cannot be used 
effectively for vascular risk prediction. In recogni-
tion of  this limitation, these epidemiological studies 
use “high-sensitivity” tests to determine CRP levels 
with excellent ﬁ  delity and reproducibility across 
the normal range.
9 In inﬂ  ammatory status, as in the 
symptomatic PAD that this study aims to prove, 
CRP levels are increased signiﬁ  cantly and thus 
standard CRP assays help in accurate measurement 
of the severity of the disease.
Non-speciﬁ  c inﬂ  ammatory markers increase in 
acute infection or trauma and in individuals with 
clinically apparent inﬂ  ammatory conditions such 
as rheumatoid arthritis or lupus. All the patients 
who had had any infectious disease or other acute 
illness such as acute coronary or limb ischemia 
within a 16-week period, and those suffering from 
chronic inﬂ  ammatory disease were excluded from 
the study. It was also ensured that the speciﬁ  c 
acute-phase inﬂ  ammatory cells and serum markers 
were similar between the three groups.
The mechanism of CRP’s association with an 
increase in the risk and severity of atherosclerotic 
disease is only suggested by diverse hypotheses. It 
is believed that CRP, in addition to being a hepatic 
marker of systemic inﬂ  ammation, could have a 
procoagulant effect associated with its capacity to 
promote the expression of tissue factor.
10
Table 3. Clinical severity of peripheral arterial disease according to C-reactive proteinplasma levels.
Size sample CRP median 
concentration
Quartil25–Quartil75 Range
Group 1 150 3.81 2.14–5.48 0.12–12.1
Group 2 130 8.33 4.38–9.19 0.83–16.5
Group 3 50 12.83 9.5–14.16 4.67–19.8
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Figure 1. Association tendency between crp and clinical severity of PAD.6
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Experimental studies suggest that CRP can 
induce activation of the complement system,
11 
bind to human neutrophils,
12 be found in the endo-
thelium of the blood vessels
13 and can be probably 
involved in the secretion of cellular adhesion 
molecules that play an important role in the leu-
kocyte adhesion and migration across the vascular 
wall—a very important step in the beginning of 
atherosclerosis.
14
On the other hand, there are also hypotheses 
that suggest that low-grade inﬂ  ammation detected 
by CRP indicates a chronic infection process. 
Currently, there are cross-sectional and case-control 
studies that have reported elevated antibody titers 
against Helicobacter pylori, Chlamydia pneu-
moniae and Cytomegalovirus in patients with a high 
prevalence of heart disease.
15 It is also possible that 
the association between CRP and atherosclerotic 
disease is a product of cytokines such as interleu-
kin-6 (IL-6) that promote leukocyte adhesion and 
stimulate CRP production. Studies have demon-
strated the relationship between inﬂ  ammation and 
endothelial dysfunction and thereby the deregulation 
in nitric oxide metabolism.
16,17
Although previous studies have shown positive 
associations between ankle-brachial index and 
measurements of hemostatic and inﬂ  ammatory 
markers,
18 there have been no known previous 
studies that have directly compared the relationship 
between CRP plasma levels in patients with symp-
tomatic PAD and the severity in the chronological 
behaviour of the disease.
This study has some limitations as it is cross-
sectional and thereby there is a difﬁ  culty in deter-
mining whether the higher CRP levels are causally 
related to the clinical severity of PAD. However, 
this relationship reinforces the important role of 
the inﬂ  ammatory pathway in the form of presenta-
tion of PAD in the symptomatic states and not 
just in the case of underlying asymptomatic disease, 
where CRP is well-known as a predictor and marker 
of developing peripheral vascular disease.
19–24 The 
second limitation is that the long-term effects of 
the surgical procedures, as could be in case of the 
inﬂ  ammatory changes at anastomotic sites, would 
be able to elevate the CRP plasma levels. Experi-
mental in vivo and pathologic studies have shown 
that inﬂ  ammatory reaction in the atherosclerotic 
plaque is exponentially greater than that produced 
in the anastomosis by the vascular wall trauma.
In conclusion, plasma levels of CRP are 
associated not only with the presence of 
atherosclerosis but also with its clinical severity in 
the target population of this study. For universality 
of this conclusion more studies are required with 
a larger target population.
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